variables: 817621
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
817621 | Bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility | patients | 2023-12-13 10:33:59 | 2024-07-25 22:54:12 | 2017-2019 | 6308 | { "unit": "patients", "numDecimalPlaces": 0 } |
0 | nrr_hivall | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#nrr_hivall | 2 | major | Number of bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility. Rifampicin is an antibiotic medication used primarily in the treatment of tuberculosis and other bacterial infections; it works by inhibiting the growth of bacteria. | [] |
This variable is calculated as the sum of the following variables: Bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility who are HIV-positive, HIV-negative and whose HIV status is unknown. | int | [] |
57337801d6b9589c3c42a3d499d4529e | 40b85b93d9bc090664a983215db177e7 |